查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949615

子宮肌瘤藥物市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類別、類型、最終用戶、地區和競爭格局分類，2021-2031年）

Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球子宮肌瘤治療市場預計將從 2025 年的 49.5 億美元成長到 2031 年的 64.2 億美元，年複合成長率為 4.43%。

該市場涵蓋促性腺激素分泌釋放激素 (GnRH) 拮抗劑和促效劑等藥物，用於緩解月經過多等症狀和縮小腫瘤。其成長主要受患者偏好轉變的驅動，患者傾向於選擇非手術、保留子宮的治療方法，以及口服藥物日益普及，因為與侵入性手術相比，口服藥物更便捷。根據美國女性健康研究協會 (Women's Health Research Association) 2025 年的預測，美國約有 2,600 萬名女性患有子宮肌瘤，這構成了一項重大的疾病負擔，亟需有效的藥物治療方案。

市場概覽
預測期 2027-2031
市場規模：2025年 49.5億美元
市場規模：2031年 64.2億美元
複合年成長率：2026-2031年 4.43%
成長最快的細分市場 黏膜下肌瘤
最大的市場 北美洲

儘管具有這種潛力，但由於新型品牌療法的高昂成本以及長期用藥帶來的安全隱患，市場成長仍面臨許多重大障礙。例如，長期荷爾蒙抑制治療可能導致骨骼密度下降等風險，從而限制治療的耐受性持續時間，並增加治療方案的複雜性。此外，昂貴的新藥還需滿足嚴格的報銷要求，這些因素阻礙了患者獲得治療，有效抑制了先進藥物療法的廣泛應用。

市場促進因素

新型口服促性腺激素分泌釋放激素 (GnRH) 拮抗劑的商業性化上市和廣泛應用，大大推動了市場成長。這些藥物提供了有效且非侵入性的治療選擇。例如，Relugolix)和林扎戈利 (linzagolix) 等治療方法為女性提供了一種便捷的口服途徑來控制月經過多等症狀，避免了手術帶來的恢復時間和風險。這種強勁的需求也體現在主要產業相關人員的財務表現中。例如，吉瑞製藥 (Gedeon Richter) 於 2025 年 11 月發布的「2025 年第一至第三季財務報告」顯示，其子宮肌瘤藥物 Lyeco 的銷售額同比成長 97.3%，凸顯了這些口服拮抗劑作為一線治療藥物的迅速普及。

同時，強大的臨床研發管線和對女性健康研究與開發的持續投入，正推動下一代治療方法的研發。投資者和製藥公司都意識到該領域存在著巨大的未滿足需求，因此加大了資金投入，以拓展手術和荷爾蒙避孕之外的治療選擇。矽谷銀行於2025年4月發布的《2025年女性健康創新報告》顯示，預計2024年，該領域的創業投資將達到26億美元，顯示市場對未來的成長充滿信心。這些資金對於應對子宮肌瘤的廣泛影響至關重要。女性健康研究協會指出，到2025年，高達80%的女性在50歲之前會罹患子宮肌瘤，這意味著大規模的患者族群需要持續的治療方法創新。

市場挑戰

全球子宮肌瘤治療市場成長的主要障礙是長期用藥相關的安全隱患，尤其是可能導致骨骼密度下降的風險。由於促性腺激素釋放激素（GnRH）拮抗劑等藥物通常會將雌激素抑製到威脅骨骼健康的水平，監管機構通常會限制治療持續時間。這種臨床限制使得這些藥物無法作為長期慢性病治療方案，從而大幅降低了每位患者的收入潛力，並阻礙了治療的連續性。因此，患者往往被迫停止有效的藥物治療，轉而選擇手術治療，導致藥物銷售量持續下降。

此外，這種安全性使得高成本品牌療法的經濟效益難以論證。保險公司和支付者採用嚴格的報銷標準，並且由於使用限制，不願承保只能暫時緩解症狀的昂貴藥物，從而阻礙了此類藥物的廣泛應用。這些限制凸顯了疾病持續帶來的經濟負擔。根據美國女性健康研究協會 (SWHR) 2025 年的估計，子宮肌瘤患者的勞動生產力損失總計達 172 億美元。這項數據強調了市場無法提供安全、長期有效的藥物療法這一現實，造成了巨大的臨床和經濟缺口，最終阻礙了整個領域的發展。

市場趨勢

聯合療法的引入正在從根本上重塑治療格局，這些療法能夠減輕低雌激素副作用，克服傳統荷爾蒙療法的安全性限制。雖然促性腺激素分泌釋放激素 (GnRH) 拮抗劑能有效縮小子宮肌瘤，但由於骨骼密度下降的風險，長期用藥歷來都是一個挑戰。為了解決這個問題，研發人員正在將固定劑量方案商業化，這些方案通常包含醋酸炔諾酮和雌二醇“替代療法”，旨在將雌激素水平維持在既不影響療效又能保護骨骼健康的範圍內。這項進展使得治療持續時間得以延長，從而提高了其在慢性病管理中的應用。根據住友製藥於 2025 年 5 月發布的“截至 2025 年 3 月的會計年度總結”，聯合治療Myfenvly 在 2024 會計年度的銷售額同比成長了 32%。

同時，隨著醫療服務提供者和患者越來越傾向於避免子宮切除等侵入性手術，第一線藥物治療的模式轉移正在加速。這項轉變的驅動力在於有效口服藥物的廣泛應用，為希望避免併發症和恢復期的女性提供了一種「保留子宮」的選擇。臨床指引也日益傾向於第一線藥物治療，而非「後續觀察」或術前治療，從而擴大了目標患者群體。這種結構性轉變也體現在產業績效中。例如，吉瑞製藥（Gedeon Richter）於2025年2月發布的《2024會計年度第四季財務報告》預測，其女性健康部門2024年的營收將成長12%，這顯示藥物治療在標準治療中的作用日益增強。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球子宮肌瘤治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（促性腺激素分泌釋放激素 (GnRH)促效劑、促性腺激素分泌釋放激素 (GnRH) 拮抗劑、黃體素釋放子宮內避孕器 (IUD) 和避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下肌瘤、肌壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
    • 依最終用戶（醫院藥局、零售藥局、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美子宮肌瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲子宮肌瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區子宮肌瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲子宮肌瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美子宮肌瘤治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球子宮肌瘤治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17232

The Global Uterine Fibroid Treatment Drugs Market is projected to expand from a valuation of USD 4.95 Billion in 2025 to USD 6.42 Billion by 2031, reflecting a compound annual growth rate of 4.43%. This market encompasses pharmaceutical agents, such as Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists, which are utilized to alleviate symptoms like menorrhagia and decrease tumor size. Growth is largely propelled by a shifting patient preference toward uterine-sparing, non-surgical interventions and the increasing accessibility of oral treatments that provide greater convenience compared to invasive procedures. As highlighted by the Society for Women's Health Research in 2025, approximately 26 million women in the United States are affected by uterine fibroids, emphasizing the significant burden of disease that demands effective pharmacological management solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.95 Billion
Market Size 2031USD 6.42 Billion
CAGR 2026-20314.43%
Fastest Growing SegmentSubmucosal Fibroids
Largest MarketNorth America

Despite this potential, market growth faces substantial obstacles due to the elevated costs of new branded therapies and safety issues related to their long-term administration. Risks such as reduced bone mineral density associated with extended hormonal suppression can limit the permissible duration of therapy and add complexity to treatment plans. When combined with strict reimbursement requirements for high-priced novel drugs, these clinical restrictions create hurdles for patient access and effectively hinder the broader adoption of advanced pharmaceutical remedies.

Market Driver

The market is being significantly advanced by the commercial launch and widespread acceptance of novel oral Gonadotropin-Releasing Hormone (GnRH) antagonists, which offer effective, non-invasive treatment options. Therapies such as relugolix and linzagolix provide women with a convenient daily oral routine to control symptoms like heavy menstrual bleeding, eliminating the recovery time and risks inherent to surgical procedures. This strong demand is reflected in the financial results of major industry stakeholders; for example, Gedeon Richter's 'Q1-Q3 2025 Earnings Report' from November 2025 indicated that sales of the uterine fibroid drug Ryeqo increased by 97.3% year-over-year, demonstrating the rapid uptake of these oral antagonists as a preferred first-line therapy.

In parallel, a strong clinical pipeline and continuous investment in women's health research and development are driving the creation of next-generation treatments. Both investors and pharmaceutical firms are acknowledging the significant unmet needs in this field, resulting in increased funding to expand options beyond surgery and hormonal contraceptives. According to the 'Innovation in Women's Health 2025' report by Silicon Valley Bank in April 2025, venture capital investment in the sector hit $2.6 billion in 2024, indicating robust confidence in future growth. This capital is essential for addressing the condition's broad impact; the Society for Women's Health Research noted in 2025 that uterine fibroids affect up to 80% of women by age 50, establishing a large demographic that requires ongoing therapeutic innovation.

Market Challenge

A major impediment to the growth of the Global Uterine Fibroid Treatment Drugs Market is safety apprehension regarding long-term use, particularly the potential for reduced bone mineral density. Since pharmaceutical agents such as GnRH antagonists frequently suppress estrogen to levels that may endanger bone health, regulatory bodies often impose limits on how long therapy can continue. This clinical restriction prevents these drugs from serving as long-term chronic care solutions, effectively limiting revenue potential per patient and interrupting the continuity of care, which often forces patients to stop effective drug therapy and return to surgical options, thereby decreasing sustained drug sales volume.

Additionally, these safety profiles make it difficult to economically justify high-cost branded treatments. Insurance providers and payers apply strict reimbursement standards, showing reluctance to cover expensive medications that offer only temporary symptom relief due to mandatory usage caps, which limits widespread adoption. The consequence of these restrictions is highlighted by the ongoing economic burden of the condition; the Society for Women's Health Research estimated in 2025 that lost work productivity among fibroid patients totaled up to $17.2 billion. This statistic underscores how the market's failure to offer safe, long-term pharmacological management leaves a significant clinical and economic void, ultimately stalling the sector's overall expansion.

Market Trends

The treatment landscape is being fundamentally reshaped by the integration of combination therapies designed to mitigate hypoestrogenic side effects, thereby overcoming the safety constraints of earlier hormonal treatments. Although Gonadotropin-Releasing Hormone (GnRH) antagonists successfully reduce fibroid size, their long-term application has historically been limited by the risk of bone mineral density loss; to counter this, developers are commercializing fixed-dose regimens that include "add-back" therapy-usually norethindrone acetate and estradiol-to keep estrogen levels within a range that preserves bone health without reducing efficacy. This advancement enables longer treatment durations, which drives adoption for chronic management, as evidenced by Sumitomo Pharma's 'Summary of Consolidated Financial Results for the Year Ended March 31, 2025' from May 2025, which reported a 32% year-over-year revenue increase for the combination therapy Myfembree in fiscal year 2024.

Concurrently, there is an accelerating paradigm shift toward utilizing pharmacological interventions as first-line therapy, as providers and patients increasingly move away from invasive surgeries like hysterectomies. This transition is driven by the rising availability of effective oral treatments that offer a "uterine-sparing" alternative, meeting the needs of women who wish to avoid the complications and recovery times associated with surgery. Clinical guidelines are adapting to endorse medical management as a primary step rather than "watchful waiting" or a precursor to surgery, which expands the target patient population; this structural change is reflected in sector performance, such as Gedeon Richter's 'Q4/FY2024 Earnings Report' from February 2025, where the Women's Healthcare division posted a 12% revenue rise in 2024, indicating the growing role of pharmaceutical management in standard care.

Key Market Players

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

Report Scope

In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Fibroid Treatment Drugs Market, By Drug Class

  • Gonadotropin-Releasing Hormone (Gnrh) Agonists
  • Gonadotropin-Releasing Hormone (Gnrh) Antagonists
  • Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
  • Non-Hormonal Medications
  • Others

Uterine Fibroid Treatment Drugs Market, By Type

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroid Treatment Drugs Market, By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroid Treatment Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroid Treatment Drugs Market.

Available Customizations:

Global Uterine Fibroid Treatment Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Fibroid Treatment Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 5.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 5.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Uterine Fibroid Treatment Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Uterine Fibroid Treatment Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Uterine Fibroid Treatment Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End User

7. Europe Uterine Fibroid Treatment Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. France Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End User

8. Asia Pacific Uterine Fibroid Treatment Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Middle East & Africa Uterine Fibroid Treatment Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User

10. South America Uterine Fibroid Treatment Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Uterine Fibroid Treatment Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Myovant Sciences Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc
  • 15.3. Abbvie Inc
  • 15.4. Ferring BV
  • 15.5. AstraZeneca
  • 15.6. Bayer AG
  • 15.7. Amring Pharmaceuticals Inc
  • 15.8. Watson Pharma Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer